GALECTIN THERAPEUTICS INC — Form SCHEDULE 13D/A
Filed August 4, 2026 · analyzed by the Ownership Agent
SCHEDULE 13D/A
— Neutral
significance 15/100
What the filing says
A Schedule 13D/A (amendment to beneficial ownership statement) was filed on 2026-08-04 for Galectin Therapeutics Inc by Richard E. Uihlein. The filing documents contain no substantive disclosure of shareholding changes, percentages, share counts, or transaction details in the text provided—only administrative headers and addresses are visible.
Why this rating
No material facts disclosed; amendment metadata only. Cannot assess shareholder stake changes or ownership shifts without actual filing content.
See more from August 4, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.